文献速递浆细胞疾病

伊沙妥昔单抗联合卡非佐米和地塞米松治疗复发多发性骨髓瘤的缓解深度与缓解动力学

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma.
PubMed 文献 · Blood Adv · 2022-01-01

IKEMA研究是一项随机、开放标签、多中心3期研究,比较伊沙妥昔单抗联合卡非佐米和地塞米松(Isa-Kd)与Kd方案治疗复发多发性骨髓瘤。中位随访20.7个月时,Isa-Kd组≥VGPR率72.6% vs Kd组56.1%,CR率39.7% vs 27.6%,MRD阴性率29.6% vs 13.0%。Isa-Kd在缓解深度上具有临床意义的改善。

要点

  • Isa-Kd组≥VGPR率72.6%,Kd组56.1%;CR率Isa-Kd组39.7%,Kd组27.6%。
  • MRD阴性率Isa-Kd组29.6%(53/179)vs Kd组13.0%(16/123),MRD阴性CR率20.1% vs 10.6%。
  • 达到MRD阴性的患者在两组中均显示更好的PFS。

核心结论

  • Isa-Kd方案在复发多发性骨髓瘤患者中较Kd方案在缓解深度上具有临床意义的改善。
  • Isa-Kd组的CR率为39.7%,质谱分析提示潜在校正后CR率可达45.8%。

研究设计与样本

  • IKEMA研究为随机、开放标签、多中心3期研究(#NCT03275285),纳入既往接受1至3线治疗的复发和/或难治性多发性骨髓瘤患者。
  • 本次分析比较Isa-Kd与Kd的缓解深度,主要终点为无进展生存期(PFS),次要终点包括总缓解率、≥VGPR率、CR率和MRD阴性率。

主要发现

  • 中位随访20.7个月时,Isa-Kd组≥VGPR率为72.6%,Kd组为56.1%;CR率Isa-Kd组为39.7%,Kd组为27.6%。
  • MRD阴性率Isa-Kd组为29.6%(53/179例),Kd组为13.0%(16/123例);MRD阴性CR率Isa-Kd组为20.1%(36/179例),Kd组为10.6%(13/123例)。
  • 达到MRD阴性的患者在两组中均显示更好的PFS。
  • MRD阴性患者中Isa-Kd的PFS治疗效应:HR 0.578(95%CI 0.052-6.405);MRD阳性患者中HR 0.670(95%CI 0.452-0.993)。
  • 探索性分析提示当前CR率和MRD阴性CR率因M蛋白干扰而被低估,潜在校正后CR率为45.8%,潜在校正后MRD阴性CR率为24.0%。

关键数值与推荐

  • MRD阴性采用二代测序在10⁻⁵灵敏度水平评估,评估对象为达到≥VGPR的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The IKEMA study (Randomized, Open Label, Multicenter Study Assessing the Clinical Benefit of Isatuximab Combined With Carfilzomib [Kyprolis®] and Dexamethasone Versus Carfilzomib With Dexamethasone in Patients With Relapse and/or Refractory Multiple Myeloma Previously Treated With 1 to 3 Prior Lines; #NCT03275285) was a randomized, open-label, multicenter phase 3 study investigating isatuximab plus carfilzomib and dexamethasone (Isa-Kd) vs Kd in patients with relapsed multiple myeloma. This subanalysis analyzed the depth of response of Isa-Kd vs Kd. The primary end point was progression-free survival (PFS); secondary end points included overall response rate, very good partial response or better (≥VGPR) rate, complete response (CR) rate, and minimal residual disease (MRD) negativity rate (assessed in patients with ≥VGPR by next-generation sequencing at a 10-5 sensitivity level). At a median follow-up of 20.7 months, deeper responses were observed in the Isa-Kd arm vs the Kd arm, with ≥VGPR 72.6% vs 56.1% and CR of 39.7% vs 27.6%, respectively. MRD negativity occurred in 53 (29.6%) of 179 patients in the Isa-Kd arm vs 16 (13.0%) of 123 patients in the Kd arm, with 20.1% (Isa-Kd, 36 of 179 patients) vs 10.6% (Kd, 13 of 123 patients) reaching MRD-negative CR status. Achieving MRD negativity resulted in better PFS in both arms. A positive PFS treatment effect was seen with Isa-Kd in both MRD-negative patients (hazard ratio, 0.578; 95% CI, 0.052-6.405) and MRD-positive patients (hazard ratio, 0.670; 95% CI, 0.452-0.993). Exploratory analysis indicates that both current CR and MRD-negative CR rates are underestimated due to M-protein interference (potential adjusted CR rate, 45.8%; potential adjusted MRD-negative CR rate, 24.0%). In conclusion, there was a clinically meaningful improvement in depth of response with Isa-Kd. The CR rate in Isa-Kd was 39.7%. Mass spectrometry suggests that the potential adjusted CR rate could reach an unprecedented 45.8% of patients treated with Isa-Kd.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Martin T, Mikhael J, Hajek R, et al. Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. Blood Adv. 2022. PMID: 35594559. doi:10.1182/bloodadvances.2021006713

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。